S Arun, Rajat Bopaiah, Souvik Paul Mazumdar 
Dealstreet

ALMT Legal Bangalore assists Excelsoft Tech on DRHP filing for ₹700 crore IPO

Excelsoft Technologies is a global vertical SaaS company focused on the learning and assessment market.

Bar & Bench

Excelsoft Technologies Limited has filed its draft red herring prospectus (DRHP) with SEBI to raise ₹700 crore through an IPO of its securities.

ALMT Legal, Bangalore acted as  the legal counsel to the issue.

The transaction team was led by S. Arun (Senior Partner) and Rajat Bopaiah (Senior Partner) along with Souvik Paul Mazumdar (Partner). The transaction team for diligence, drafting and compliance comprised of Natasha Ponnappa (Senior Associate) and Associates Nikhil Krishna, Zac Toby, Gunjan Jain, Danika Joplin and Mahimna Dave.

Excelsoft

Excelsoft Technologies is a global vertical SaaS company focused on the learning and assessment market. The company provide technology-based solutions across diverse learning and assessment segments through our cloud-based platforms.

The IPO comprises a fresh equity issue of up to ₹210 crore and an offer for sale (OFS) of shares worth up to ₹490 crore by promoters Pedanta Technologies Private Limited and Dhananjaya Sudhanva. Proceeds from the fresh issue are earmarked for capital expenditure, including the purchase of land and construction of a new facility, upgrading IT infrastructure, and general corporate purposes. In the financial year 2023-24, Excelsoft reported revenues of ₹198.3 crore and a profit after tax of ₹12.75 crore.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

Producers of Tamil film Kaithi move Bombay HC accusing Bholaa's makers of violating remake rights

Deepika newspaper tenders apology before Kerala High Court for misleading report on court order

Delhi High Court denies relief to man accused of duping woman of ₹12 crore by selling fake DLF Camellias flat

Veritas Legal elevates Nainaaz Irani and Rohini Jaiswal to Partnership

Dr Reddy’s tells Delhi HC it will not launch oral diabetes drug within Novo Nordisk patent range

SCROLL FOR NEXT